Inject-able Buprenex Abuse
Although the occurrence of injectable-buprenex abuse is extremely rare in the US, there are a few cases. As a general rule, Buprenorphine which is the active ingredient in injectable-buprenex abuse, is used for opiate addiction treatment. The drug buprenorphine began to be marketed in the 1980’s in the United States, as a controlled, Schedule V painkiller.
Up until a few years ago, the low dose injectable-buprenex form was the only buprenorphine product that was available in the US. Surprisingly little of injectable-buprenex abuse has been reported, and very little of the product is diverted for non medical use in the United States. However, trafficking in the drug and injectable-buprenex abuse has been reportedly taking place in parts of Europe and the world.
The FDA (Food and Drug Administration) has recently approved two other buprenorphine products called Suboxone and Subutex for use. This use of course is specifically limited to the treatment of opiate addiction. In general, both the approved products are the higher dose versions, containing 2 to 8 mg of buprenorphine in a tablet for, to be used sublingually by placing under the tongue.
Subutex as a product contains only buprenorphine, making it a single entity drug, while Suboxone on the other hand is a combination drug containing both buprenorphine and naloxone. All the products containing buprenorphine, including the low dose injectable-buprenex form, have been moved to Schedule III, after a review of the available data and on the basis of a recommendation from the Department of Health and Human Services, in 2002.
Legally, Buprenorphine in the form of the low dosage injectable-buprenex is meant to be used for the purposes of pain control. The other higher dose products such as Suboxone and Subutex, are supposed to be used in the treatment of addiction. The Narcotic Addict Treatment Act has been amended in 2001 and 2005, allowing, as a result of these amendments, the prescription of Schedule III-V narcotic drugs.
These drugs, which are approved by the FDA for the treatment of narcotic addiction, can be prescribed, for this purpose, for only 30 or fewer patients at any time, per physician. These are mean to be prescribed by qualified physicians, who are under certification of the DHHS, to prescribe these buprenorphine products, for use in narcotic treatment programs that take place outside of the usual clinic-based programs.
As of now, the only narcotic treatment drugs that meet the requirements specified by the above exception, are the buprenorphine based drugs Suboxone and Subutex. These are used for the treatment and detox of addiction to other opiates, as well as the treatment of injectable-buprenex abuse. In the US today, there are close to six thousand physicians approved for office based treatment of injectable-buprenex abuse and narcotic addiction. These physicians have been approved by the Substance Abuse and Mental Health Services Administration as well as the DEA.
As with the other common opiates that are generally abused, the buprenorphine products also produce the usual narcotic related states of high euphoria. In many other countries, general buprenorphine abuse, and specifically injectable-buprenex abuse has taken place via all the possible routes of administration, ranging from the sublingual tablets, to the intranasal sprays, or snorting, as well as the injectionform. Injectable-buprenex abuse has become popular as a substitute for heroin abuse, and injectable-buprenex has become a primary drug of abuse. In European countries like Ireland, Scotland, and France, as well as in New Zealand and India, there are large scale reports of the drug abusing populations getting into injectable-buprenex abuse as well as other buprenorphine products in combination with benzodiazepine.
However, surprisingly, there is practically no data available, which could show the range of buprenorphine abuse in the US.
Although the occurrence of injectable-buprenex abuse is extremely rare in the US, there are a few cases. As a general rule, Buprenorphine which is the active ingredient in injectable-buprenex abuse, is used for opiate addiction treatment. The drug buprenorphine began to be marketed in the 1980’s in the United States, as a controlled, Schedule V painkiller.
Up until a few years ago, the low dose injectable-buprenex form was the only buprenorphine product that was available in the US. Surprisingly little of injectable-buprenex abuse has been reported, and very little of the product is diverted for non medical use in the United States. However, trafficking in the drug and injectable-buprenex abuse has been reportedly taking place in parts of Europe and the world.
The FDA (Food and Drug Administration) has recently approved two other buprenorphine products called Suboxone and Subutex for use. This use of course is specifically limited to the treatment of opiate addiction. In general, both the approved products are the higher dose versions, containing 2 to 8 mg of buprenorphine in a tablet for, to be used sublingually by placing under the tongue.
Subutex as a product contains only buprenorphine, making it a single entity drug, while Suboxone on the other hand is a combination drug containing both buprenorphine and naloxone. All the products containing buprenorphine, including the low dose injectable-buprenex form, have been moved to Schedule III, after a review of the available data and on the basis of a recommendation from the Department of Health and Human Services, in 2002.
Legally, Buprenorphine in the form of the low dosage injectable-buprenex is meant to be used for the purposes of pain control. The other higher dose products such as Suboxone and Subutex, are supposed to be used in the treatment of addiction. The Narcotic Addict Treatment Act has been amended in 2001 and 2005, allowing, as a result of these amendments, the prescription of Schedule III-V narcotic drugs.
These drugs, which are approved by the FDA for the treatment of narcotic addiction, can be prescribed, for this purpose, for only 30 or fewer patients at any time, per physician. These are mean to be prescribed by qualified physicians, who are under certification of the DHHS, to prescribe these buprenorphine products, for use in narcotic treatment programs that take place outside of the usual clinic-based programs.
As of now, the only narcotic treatment drugs that meet the requirements specified by the above exception, are the buprenorphine based drugs Suboxone and Subutex. These are used for the treatment and detox of addiction to other opiates, as well as the treatment of injectable-buprenex abuse. In the US today, there are close to six thousand physicians approved for office based treatment of injectable-buprenex abuse and narcotic addiction. These physicians have been approved by the Substance Abuse and Mental Health Services Administration as well as the DEA.
As with the other common opiates that are generally abused, the buprenorphine products also produce the usual narcotic related states of high euphoria. In many other countries, general buprenorphine abuse, and specifically injectable-buprenex abuse has taken place via all the possible routes of administration, ranging from the sublingual tablets, to the intranasal sprays, or snorting, as well as the injectionform. Injectable-buprenex abuse has become popular as a substitute for heroin abuse, and injectable-buprenex has become a primary drug of abuse. In European countries like Ireland, Scotland, and France, as well as in New Zealand and India, there are large scale reports of the drug abusing populations getting into injectable-buprenex abuse as well as other buprenorphine products in combination with benzodiazepine.
However, surprisingly, there is practically no data available, which could show the range of buprenorphine abuse in the US.
For additional information on addiction treatment or the drug
Suboxone,
Call now 1-888-Suboxone or 1-888-782-6966
E-mail: Support@SoftLandingRecovery.com>
Content provided by the Editorial Board.
This article is written by a freelance writer. It might not reflect the views and opinions of Soft Landing ltd. or its staff but has been placed here
so that our visitors may get an idea of how others think of the topic.
Information on this page last updated on 09/17/2007